肿瘤患者静脉血栓栓塞抗凝出血与复发风险研究进展

肿瘤相关静脉血栓栓塞症(cancer-associated venous thromboembolism, CAVTE)为肿瘤患者在疾病进程中的常见并发症和死亡原因。其静脉血栓栓塞症(venous thromboembolism, VTE)复发和抗凝后严重出血的高风险可能会导致治疗延误和死亡率增加。目前, 国内外指南并未推荐对所有门诊患者直接进行一级预防, 但建议在化疗前评估发生静脉血栓栓塞的个体风险。本文对目前肿瘤患者静脉血栓栓塞抗凝出血与复发研究进展以及现行VTE防治指南和VTE风险评估模型进行综述。 

Risks of bleeding and recurrence in cancer-associated venous thromboembolism after anticoagulation therapy

Cancer-associated venous thromboembolism (CAVTE) is a common complication and cause of death in cancer patients.The high risks for VTE recurrence and severe bleeding after the cessation of anticoagulation therapy may lead to delayed treatment and increased mortality.Current guidelines at home and abroad do not recommend direct primary prevention; instead, they recommend the assessment of the risk of VTE in each patient before chemotherapy.In recent years, scholars have been committed to developing accurate prediction tools for the risk assessment of VTE in cancer patients.In this paper, we review the current studies on bleeding and recurrence risks associated with CAVTE after anticoagulation therapy, guidelines for the prevention and treatment of VTE, and risk assessment models for VTE.